Thermo Fisher Scientific Inc. $TMO Shares Acquired by Cryder Capital Partners LLP

Key Points

• Cryder Capital Partners LLP increased its Thermo Fisher stake by 9.3% in Q4 to 376,681 shares (≈$218.3M), making TMO about 12.9% of Cryder's holdings and its third-largest position.
• Several large institutions (Vanguard, Capital World, Franklin, BNY Mellon, MFS) also raised positions and institutional ownership sits at 89.23%, while insiders have sold 5,800 shares (~$2.96M) in the last three months, leaving insiders with 0.33% ownership.
• Thermo Fisher beat Q results (EPS $5.44 vs. $5.25 estimate; revenue $11.01B), provided FY2026 EPS guidance of 24.64–25.12, and raised its quarterly dividend to $0.47 (annualized $1.88, yield ~0.4%).

Cryder Capital Partners LLP increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 376,681 shares of the medical research company's stock after buying an additional 32,005 shares during the quarter. Thermo Fisher Scientific comprises approximately 12.9% of Cryder Capital Partners LLP's holdings, making the stock its 3rd largest position. Cryder Capital Partners LLP owned approximately 0.10% of Thermo Fisher Scientific worth $218,268,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the period. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the period. Franklin Resources Inc. raised its position in shares of Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the period. Bank of New York Mellon Corp raised its position in shares of Thermo Fisher Scientific by 54.7% during the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Thermo Fisher Scientific by 5.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company's stock worth $1,789,148,000 after purchasing an additional 150,668 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 5,800 shares of company stock valued at $2,963,544. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $466.74 on Wednesday. The company has a market capitalization of $173.45 billion, a price-to-earnings ratio of 25.66, a P/E/G ratio of 2.05 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The stock's fifty day simple moving average is $495.23 and its 200-day simple moving average is $547.61.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TMO shares. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. DZ Bank assumed coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 price target on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Finally, Wells Fargo & Company set a $683.00 price target on Thermo Fisher Scientific in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $623.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.